The Value of Serum Amyloid A Levels in Familial Mediterranean Fever to Identify Occult Inflammation During Asymptomatic Periods

Objective The aim of this observational study was to evaluate whether there was any correlation between the acute phase reactants in children with familial Mediterranean fever (FMF) during attack and attack-free periods. Methods The study was conducted between June 2016 and January 2018. Clinical features and laboratory parameters of children with FMF during attack and attack-free periods were recorded longitudinally. Results The cohort consisted of 168 children with FMF (84 boys, 84 girls). Median values of acute phase reactants during FMF attacks were 433.5 mg/L (34.0–1780.0 mg/L) for serum amyloid A (SAA), 56.7 mg/L (7.6–379.0 mg/L) for C-reactive protein (CRP), and 37.5 mm/h (5–100 mm/h) for erythrocyte sedimentation rate (ESR). Median values for the same tests in attack-free periods were 3.2 mg/L (0.1–25.0 mg/L), 1.7 mg/L (0.1–12.7 mg/L), and 8 mm/h (1–30 mm/h), respectively. Correlation analyses showed that SAA and CRP were highly correlated in FMF attack (r = 0.67, p < 0.01), but no correlation was found between SAA and ESR levels. C-reactive protein was elevated in 13.6%, ESR in 20.8%, and SAA in 28.5% of the patients during attack-free period. Age at onset, sex of the patients, and characteristics of attacks were found to be not associated with elevated SAA in attack-free period. On the other hand, having homozygous exon 10 mutation and having elevated CRP were found to be associated with high SAA in attack-free period. Conclusions C-reactive protein and SAA correlate well with FMF attacks. Therefore, checking for SAA during a FMF attack is not required. However, SAA seems to be the most sensitive method for demonstrating subclinical inflammation in attack-free period. Thus, checking SAA levels might be a valuable tool in selected FMF patients.

[1]  F. Yalçınkaya,et al.  Sacroiliitis in Children With Familial Mediterranean Fever , 2019, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[2]  R. Papa,et al.  Secondary, AA, Amyloidosis. , 2018, Rheumatic diseases clinics of North America.

[3]  S. Masters,et al.  An Update on Autoinflammatory Diseases: Inflammasomopathies , 2018, Current Rheumatology Reports.

[4]  H. Alpay,et al.  Polyarteritis nodosa in case of familial Mediterranean fever. , 2018, The Turkish journal of pediatrics.

[5]  S. Özen,et al.  Familial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for Management , 2017, Front. Immunol..

[6]  S. Amselem,et al.  Concordance between CRP and SAA in familial Mediterranean fever during attack-free period: A study of 218 patients. , 2017, Clinical biochemistry.

[7]  A. Elhan,et al.  Late-onset disease is associated with a mild phenotype in children with familial Mediterranean fever , 2016, Clinical Rheumatology.

[8]  S. Ozen,et al.  What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review , 2016, Rheumatology International.

[9]  H. Şenol,et al.  Could pentraxin-3 be a new marker for subclinical inflammation in familial Mediterranean fever? , 2015, Pediatric Rheumatology.

[10]  N. Wulffraat,et al.  Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever , 2015, Annals of the rheumatic diseases.

[11]  M. Fändrich,et al.  AA Amyloidosis : Pathogenesis and Targeted Therapy Gunilla , 2014 .

[12]  A. Elhan,et al.  Can colchicine response be predicted in familial Mediterranean fever patients? , 2014, Rheumatology.

[13]  A. Martini,et al.  Increased NLRP3-dependent interleukin 1β secretion in patients with familial Mediterranean fever: correlation with MEFV genotype , 2013, Annals of the rheumatic diseases.

[14]  N. Akar,et al.  The value of procalcitonin measurements in children with familial Mediterranean fever , 2012, Rheumatology International.

[15]  I. Ben-Zvi,et al.  Chronic inflammation in FMF: markers, risk factors, outcomes and therapy , 2011, Nature Reviews Rheumatology.

[16]  C. Cray,et al.  Acute phase response in animals: a review. , 2009, Comparative medicine.

[17]  A. Elhan,et al.  A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. , 2009, Rheumatology.

[18]  B. Reichman,et al.  A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. , 2007, Seminars in arthritis and rheumatism.

[19]  Caroline A Sabin,et al.  Natural history and outcome in systemic AA amyloidosis. , 2007, The New England journal of medicine.

[20]  A. Elhan,et al.  The value of the levels of acute phase reactants for the prediction of familial Mediterranean fever associated amyloidosis: a case control study , 2007, Rheumatology International.

[21]  D. Booth,et al.  Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. , 2006, Rheumatology.

[22]  J. Baehring Laboratory Investigations , 2005, Journal of Neuro-Oncology.

[23]  S. Akpek,et al.  Polyarteritis nodosa in a case of familial Mediterranean fever , 2004, Pediatric Nephrology.

[24]  A. Bakkaloğlu,et al.  Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. , 2003, Clinical and experimental rheumatology.

[25]  A. Larsson,et al.  Correlations between serum amyloid A protein and C‐reactive protein in infectious diseases , 2003, Scandinavian journal of clinical and laboratory investigation.

[26]  H. Yazici,et al.  Acute phase response in familial Mediterranean fever , 2002, Annals of the rheumatic diseases.

[27]  Ian Todd,et al.  Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes , 1999, Cell.

[28]  A. Komatsuda,et al.  [Secondary (AA) amyloidosis]. , 1998, Ryoikibetsu shokogun shirizu.

[29]  D. Zemer,et al.  Criteria for the diagnosis of familial Mediterranean fever. , 1997, Arthritis and rheumatism.